<DOC>
	<DOCNO>NCT00607581</DOCNO>
	<brief_summary>The treatment light-chain ( AL ) amyloidosis direct plasma cell produce light-chain forming amyloid deposit . The plasma cell kill growth stop drug use chemotherapy , cyclophosphamide , steroid , dexamethasone , drug stimulate immune system , lenalidomide . The present trial study efficacy safety combination cyclophosphamide , lenalidomide dexamethasone patient AL amyloidosis previously treat need therapy .</brief_summary>
	<brief_title>Cyclophosphamide , Lenalidomide Dexamethasone ( CLD ) Previously Treated Patients With AL Amyloidosis</brief_title>
	<detailed_description>This study include previously treat patient AL amyloidosis . Primary objective determine hematologic organ response rate association cyclophosphamide , lenalidomide dexamethasone ( CLD ) . Secondary objective - determine safety CLD , - determine time response CLD , - determine duration response CLD , - ass survival AL amyloidosis patient treat CLD . Patients receive 28-day cycle cyclophosphamide day 1 , 8 15 , oral lenalidomide day 1-21 oral dexamethasone day 1 , 8 , 15 , 22 . Up 9 course perform one follow endpoint meet : - completion cycle 9 , - complete hematologic remission observe cycle 3 6 , - partial hematologic response associate organ response cycle 6 . - response cycle 3 6 . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Diagnosis AL amyloidosis . Evidence monoclonal light chain serum and/or urine immunofixation electrophoresis . Elevated circulate free light chain ( type identify immunofixation ) upper limit normal range abnormal kappa/lambda ratio . Previously treat require treatment . Symptomatic organ involvement . Bone marrow plasma cell &lt; 30 % . Echocardiographic ejection fraction &gt; 40 % . Troponin I &lt; 0.1 ng/mL . Hemoglobin &gt; 10 g/dL . Absolute neutrophil count &gt; 1500/uL . Platelet count &gt; 140000/uL . Total bilirubin &lt; 2.5 mg/dL . Alkaline phosphatase &lt; 4 x upper reference limit ( u.r.l. ) . ALT &lt; 3 x u.r.l.. Glomerular filtration rate &gt; 30 mL/min . Performance status ECOG 13 . Female subject childbearing potential must two negative pregnancy test prior start study drug . Prior treatment association cyclophosphamide , lenalidomide dexamethasone lenalidomide . Requirement concomitant chemotherapy , immunotherapy radiotherapy , investigational ancillary therapy . Presence active malignancy , exception nonmelanoma skin cancer , cervical cancer , treat earlystage prostate cancer provide prostate specific antigen within normal limit . Clinically overt multiple myeloma . Uncontrolled infection . New York Heart Association ( NYHA ) class 4 heart failure . Enzyme document myocardial infarction within 6 month enrollment . Grade 2 3 atrioventricular block ( Mobitz type I permit ) . Repetitive ventricular arrhythmia 24 h Holter electrocardiogram spite treatment amiodarone . Supine systolic blood pressure &lt; 90 mmHg , symptomatic orthostatic hypotension , decrease systolic blood pressure stand &gt; 20 mmHg spite treat orthostatic hypotension . Prior history thrombosis venous thromboembolism pulmonary embolism . Prior diagnosis antiphospholipid antibody lupus anticoagulant , factor V Leiden mutation , prothrombin G21210A mutation , antithrombin , protein C S deficiency . Indication receive clopidogrel , ticlopidine warfarin . Factor X level &lt; 20 % . Poorly control diabetes mellitus ( receive antidiabetic agent , subject must stable dose least 3 month ) . Previous ongoing psychiatric illness ( exclusion reactive depression ) . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>dexamethasone</keyword>
</DOC>